Andrea Kuenzli

Learn More
BACKGROUND There is insufficient evidence whether the benefit of adding angiotensin II receptor blockers (ARBs) to angiotensin-converting enzyme (ACE) inhibitors outweighs the increased risk of adverse effects in patients with heart failure. METHODOLOGY/PRINCIPAL FINDINGS Two independent reviewers searched and abstracted randomized controlled trials of(More)
  • 1